33469-15-7

Basic information

• Product Name: 2-(4-Chlorophenyl)-4-(trifluoromethyl)-1H-imidazole
• Synonyms: 2-(4-CHLOROPHENYL)-4-(TRIFLUOROMETHYL)-1H-IMIDAZOLE;2-(4-Chlorophenyl)-4-(trifluoromethyl)-1H-;1H-IMidazole, 2-(4-chlorophenyl)-5-(trifluoroMethyl)-;2-(4-chlorophenyl)-5-(trifluoromethyl)-1H-Imidazole
• CAS NO: 33469-15-7
• Molecular Formula: C₁₀H₆ClF₃N₂
• Molecular Weight: 246.62
• Product Categories: Heterocycle
• Mol File: 33469-15-7.mol
• Article Data: 7

Chemical Properties

• Melting Point: 218-221 °C
• Boiling Point: 362.1 °C at 760 mmHg
• Flash Point: 172.8 °C
• Appearance: /
• Density: 1.436 g/cm³
• Vapor Pressure: 0.000882mmHg at 25°C
• Refractive Index: 1.554
• Storage Temp.: 2-8°C
• PKA: 10.09±0.10(Predicted)
• CAS DataBase Reference: 2-(4-Chlorophenyl)-4-(trifluoromethyl)-1H-imidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-Chlorophenyl)-4-(trifluoromethyl)-1H-imidazole(33469-15-7)
• EPA Substance Registry System: 2-(4-Chlorophenyl)-4-(trifluoromethyl)-1H-imidazole(33469-15-7)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 33469-15-7(Hazardous Substances Data)

Usage

General Description

2-(4-Chlorophenyl)-4-(trifluoromethyl)-1H-imidazole is a chemical compound that belongs to the class of organic compounds known as 1-heteroarylalkylamines. It comprises of an imidazole ring, which is a type of heterocycle that is both aromatic and azole, coupled with a chlorophenyl group and a trifluoromethyl group. The chlorophenyl group contains a phenyl ring (a type of aromatic hydrocarbon) substituted with a chlorine atom, and the trifluoromethyl group contains a carbon atom bound to three fluorine atoms and one carbon atom. 2-(4-Chlorophenyl)-4-(trifluoromethyl)-1H-imidazole, like many heteroaromatic compounds, may play a significant role in various biological and pharmacological activities, although specific uses are not readily available in common literature.

InChI:InChI=1/C8H7BrFNO/c9-5-8(11-12)6-1-3-7(10)4-2-6/h1-4,12H,5H2/b11-8-

Upstream product

• 104-88-1 4-chlorobenzaldehyde 
• 431-67-4 1,1-dibromo-3,3,3-trifluoroacetone 

Downstream Products

• 279251-15-9 2-(4-chlorophenyl)-1H-imidazole-4-carbaldehyde 
• 279250-69-0 2-(4-chlorophenyl)-4-(N-methyl-N-methoxyaminocarbonyl)-1H-imidazole 
• 34626-05-6 2-(4-chlorophenyl)-1H-imidazole-5-carboxylic acid 
• 1276122-55-4 2-(2-(4-chlorophenyl)-1H-imidazol-4-yl)benzo[d]oxazole-5-carbonitrile 
• 1276122-64-5 C₁₂H₁₀ClN₅S 
• 1276122-63-4 C₁₂H₁₀ClN₅S 
• 34626-05-6 2-(4-chlorophenyl)-4-carboxy-1H-imidazole 

Relevant articles and documents

Discovery of novel 2-aryl-4-bis-amide imidazoles (ABAI) as anti-inflammatory agents for the treatment of inflammatory bowel diseases (IBD)

A series of 2-Aryl-4-Bis-amide Imidazoles (ABAI-1 to 30) were designed as anti-inflammatory agents. These compounds were synthesized and evaluated for the in vitro anti-inflammatory activities (inhibition of NO production and release of inflammatory cytok

Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120

In our attempt to optimize the lead HIV-1 entry antagonist, NBD-11021, we present in this study the rational design and synthesis of 60 new analogues and determination of their antiviral activity in a single-cycle and a multicycle infection assay to derive a comprehensive structure-activity relationship (SAR). Two of these compounds, NBD-14088 and NBD-14107, showed significant improvement in antiviral activity compared to the lead entry antagonist in a single-cycle assay against a large panel of Env-pseudotyped viruses. The X-ray structure of a similar compound, NBD-14010, confirmed the binding mode of the newly designed compounds. The in vitro ADMET profiles of these compounds are comparable to that of the most potent attachment inhibitor BMS-626529, a prodrug of which is currently undergoing phase III clinical trials. The systematic study presented here is expected to pave the way for improving the potency, toxicity, and ADMET profile of this series of compounds with the potential to be moved to the early preclinical development.

Trifluoromethylimidazoles and a method for their preparation

4(5)-Trifluoromethylimidazoles having optional substituents in the 1 and 2 positions are provided. The novel 4(5)-trifluoromethylimidazoles are prepared by reacting a 1,1-dihalo-3,3,3-trifluoroacetone compound with an appropriate carboxaldehyde and ammoni